Halia Therapeutics has presented serine/threonine-protein kinase Nek7 inhibitors reported to be useful for the treatment of cancer, asthma, obesity, type 2 diabetes, hepatitis, peritonitis, neurodegeneration and psoriasis, among others.
The development of cancer after p53 inactivation is determined by a series of genomic changes that occur in four steps. The loss of heterozygosity of TP53 (the gene encoding p53 in humans, named Trp53 in mice) is followed by an accumulation of deletions, genome doubling, and the emergence of gains and amplifications.
Sanofi SA has terminated development of amcenestrant, an oral selective estrogen receptor degrader (SERD), following an interim analysis of data from a phase III trial in estrogen-receptor-positive advanced breast cancer patients. The company has also halted all other studies of the drug, including a phase III study in patients with early stage breast cancer.
Hepatocellular carcinoma (HCC) still remains a global health challenge as it shows genetic heterogeneity and limited therapy response. In a new study, the cellular responses in HCC that accompany the nearly universal repression of urea cycle enzymes and consequent arginine auxotrophy were investigated, since previous findings demonstrated that that HCC consistently represses urea cycle gene expression and thus become auxotrophic for exogenous arginine becoming severe disease.
Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) has patented thiazolopyrimidones acting as discoidin domain-containing receptor 1 (DDR1) and/or DDR2 inhibitors reported to be useful for the treatment of atherosclerosis, cancer, cirrhosis, hepatic fibrosis, pulmonary fibrosis, lupus nephritis, osteoarthritis and rheumatoid arthritis, among others.
Ascentage Pharma has divulged spirocyclic indenes acting as GTPase KRAS (Gly12Cys mutant) inhibitors reported to be useful for the treatment of cancer.
Guangdong Newopp Biopharmaceuticals has disclosed Son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.
Orna Therapeutics Inc., which is pioneering a novel circular RNA protein expression technology in several therapeutic areas, has achieved lift-off. The Cambridge, Mass.-based company has closed a broadly based alliance in infectious disease and oncology with Merck & Co. Inc., under which it is getting $150 million up front and up to $3.5 billion in development, regulatory and sales-based milestones. In addition, Merck, of Rahway, N.J., is investing another $100 million in Orna’s equity, as part of its $221 million series B round, which the company also disclosed on Aug. 16.
Canwell Biotech Ltd. raised more than ¥100 million (US$14.8 million) in a series A+ financing. The funds will help accelerate trials for its pipeline of anticancer assets, such as the TLR7 agonist CAN-1012, and preclinical development of other projects too, CEO Henry Yu told BioWorld. The State Development and Investment Corporation Venture Capital Co. Ltd. was the round’s sole investor.
Glubio Therapeutics Inc. has raised $22 million in a series A+ round to support the development of its targeted protein degradation drugs. With the investment, Glubio expects to file INDs for two molecular glue degraders for hematological malignancies in early 2023 in both China and the U.S.
RSS
